GENB says AI drug discovery advances lead GB-0895 program
The company cites AI-driven therapeutics development, including lead program GB-0895 for asthma and COPD, and efforts in oncology to reduce ADC toxicities, supported by partnerships and cash.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.